Scarica l'app Stockscreener
27.96
0.39%
-0.11
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
STATE STREET CORP Acquires Additional Shares in Agios Pharmaceuticals Inc - GuruFocus
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - Finviz
Brokers Offer Predictions for AGIO FY2030 Earnings - MarketBeat
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Q4 2025 slides: PYRUKYND revenue surges 86%, thalassemia launch underway - Investing.com Canada
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insight - GuruFocus
Agios Pharmaceuticals (AGIO) Files Automatic Mixed Securities Shelf - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Does Agios Pharmaceuticals Inc. have a competitive edgeRate Cut & Smart Swing Trading Techniques - mfd.ru
Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlight - GuruFocus
Does Agios Pharmaceuticals Inc. have high return on assetsInflation Watch & Smart Allocation Stock Reports - mfd.ru
AGIO: HC Wainwright & Co. Raises Price Target to $65 with Buy Ra - GuruFocus
Truist Securities raises Agios Pharma stock price target to $39 on pipeline progress - Investing.com Canada
HC Wainwright Issues Positive Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Posts Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating - TipRanks
Earnings call transcript: Agios Pharm Q4 2025 sees strong revenue growth - Investing.com Canada
AGIO: Strong 2025 growth, ACTIVASE launch momentum, and key pipeline catalysts set for 2026 - TradingView
AGIOS PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Q4 2025 Revenue Beat and Narrower Loss - ChartMill
Agios Pharmaceuticals: Q4 Earnings Snapshot - kare11.com
Agios Pharmaceuticals: Fourth Quarter Earnings Overview - Bitget
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Agios Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Availability of AQVESME™ for Thalassemia - Quiver Quantitative
Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q4 Revenue $20.0M, vs. FactSet Est of $12.1M - marketscreener.com
Press Release: Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - 富途牛牛
Avoiding Lag: Real-Time Signals in (AGIO) Movement - Stock Traders Daily
Agios Pharm set to report earnings amid thalassemia drug rollout By Investing.com - Investing.com Canada
Analyst Upgrade: Is Agios Pharmaceuticals Inc stock showing strong momentumRate Hike & Community Supported Trade Ideas - baoquankhu1.vn
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Unpacking a Potential 36% Upside for Investors - DirectorsTalk Interviews
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Agios Pharmaceuticals (AGIO) Valuation Check After Extended Share Price Weakness - Sahm
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Agios Pharmaceuticals (AGIO) Projected to Post Earnings on Thursday - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Agios Pharmaceuticals (AGIO): Investor Outlook On A Biotech With 30.5% Upside Potential - DirectorsTalk Interviews
Discipline and Rules-Based Execution in AGIO Response - Stock Traders Daily
Bull Bear: Does ProShares Trust ProShares Ultra Energy stock benefit from AI growthTrade Analysis Report & Intraday High Probability Alerts - baoquankhu1.vn
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - bioworld.com
Recap Report: Is Agios Pharmaceuticals Inc stock showing strong momentumDividend Hike & Low Drawdown Investment Ideas - baoquankhu1.vn
Agios begins U.S. launch of thalassemia drug following FDA approval By Investing.com - Investing.com Nigeria
Swing Trade: Is Agios Pharmaceuticals Inc stock overvalued or fairly pricedMarket Risk Report & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Summary: Does Agios Pharmaceuticals Inc have a competitive edge2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - The Manila Times
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - GlobeNewswire Inc.
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche - Barchart.com
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC) - The Globe and Mail
Is Agios Pharmaceuticals (AGIO) Offering A Compelling Entry Point After Recent Share Price Swings - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory - Finviz
Pharma News: Will Agios Pharmaceuticals Inc face regulatory challengesWeekly Gains Report & Daily Momentum Trading Reports - baoquankhu1.vn
What is Agios Pharmaceuticals Inc.’s market positionQuarterly Growth Report & Fast Moving Trade Plans - bollywoodhelpline.com
Q2 EPS Estimate for Agios Pharmaceuticals Boosted by Analyst - MarketBeat
A Look At Agios Pharmaceuticals (AGIO) Valuation After AQVESME FDA Approval And Commercial Launch - Sahm
Is Agios’ AQVESME Thalassemia Launch and Sickle Cell Pathway Altering The Investment Case For Agios Pharmaceuticals (AGIO)? - Sahm
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sectors Review: Is Agios Pharmaceuticals Inc stock influenced by commodity pricesEarnings Performance Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):